Alternative asset manager Blackstone on Friday announced that its private equity funds have entered into a definitive agreement to acquire Nucleus Network, the largest phase one clinical trial provider in Australia.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
